AGEs and Cardiovascular Diseases in Patients With End-Stage Renal Diseases

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 128-133

  Nishizawa, Yoshiki ^a   Koyama, Hidenori ^a,b   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGININE; DRUG DERIVATIVE; LYSINE; PENTOSIDINE; SERUM ALBUMIN;

ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ARGININE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; OXIDATIVE STRESS; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN; VASCULAR STIFFNESS;

EID: 84855169046     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.019     Document Type: Article

References (20)

1. Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. NEngl J Med 1974, 290:697-701.
2. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
3. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
5. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
6. Hostetter T.H. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004, 351:1344-1346.
7. Miyata T., Maeda K., Kurokawa K., van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997, 12:255-258.
8. Koyama H., Nishizawa Y. Cardiovascular complications in renal failure: implications of advanced glycation end-products and their receptor, RAGE. Oxidative Stress in Applied Basic Research and Clinical Practice 'Renal Disorders' 2011, 257-292. The Humana Press/Springer Science, New York, NY. T. Miyata, K.U. Eckardt, M. Nangaku (Eds.).
9. Meerwaldt R., Hartog J.W., Graaff R., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005, 16:3687-3693.
10. Koyama H., Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. Eur J Clin Invest 2010, 40:623-635.
11. Ueno H., Koyama H., Tanaka S., et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008, 57:1452-1457.
12. Kass D.A., Shapiro E.P., Kawaguchi M., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
13. Sakata N., Imanaga Y., Meng J., et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999, 142:67-77.
14. Suliman M.E., Stenvinkel P., Jogestrand T., et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006, 66:418-425.
15. Ueno H., Koyama H., Fukumoto S., et al. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 2011, 60. 453-439.
16. Taki K., Takayama F., Tsuruta Y., Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006, 70:218-224.
17. Roberts M.A., Thomas M.C., Fernando D., Macmillan N., Power D.A., Ierino F.L. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 2006, 21. 1611-617.
18. Wagner Z., Molnar M., Molnar G.A., et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 2006, 47:294-300.
19. Schwedler S.B., Metzger T., Schinzel R., Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002, 62:301-310.
20. Busch M., Franke S., Muller A., et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004, 66:338-347.